Komori
Changes in Officers4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice of Personnel Changes at a Subsidiary

Officers at 3 subsidiaries will change. At 持田製薬販売, the representative director and president will change, and the former president will become an advisor.

Worth reading
43Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Incoming appointee

4 items
Scheduled Appointment DateEffective 25 June 2026
Makino Junichi (牧野 純一)
Previous positionNot disclosed
New positionDirectors
Nakano Reiko (中野 玲子)
Previous positionNot disclosed
New positionStatutory Auditors
Miyajima Kenji (宮嶋 謙二)
Previous positionNot disclosed
New positionDirectors
Ishii Satoshi (石井 智)
Previous positionExecutive Vice President and Director
New positionRepresentative Director and President, concurrently General Manager of the Sales Promotion Department

Departing officer

6 items
Date of departureEffective 25 June 2026
Kawakami Yutaka (川上 裕)Next role stated
Former PositionDirectors
New positionRetirement
Takeda Masayoshi (竹田 雅好)Next role stated
Former PositionStatutory Auditors
New positionRetirement
Sagisaka Keiichi (匂坂 圭一)Next role stated
Former PositionDirectors
New positionRetirement
Kawakami Yutaka (川上 裕)Next role stated
Former PositionDirectors
New positionRetirement
Takeda Masayoshi (竹田 雅好)Next role stated
Former PositionStatutory Auditors
New positionRetirement
Fukuchi Kazumasa (福地 一雅)Next role stated
Former PositionRepresentative Director and President, concurrently General Manager of the Sales Promotion Department
New positionAdviser

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Whether the incumbent will remain in office (whether they will retain their position)

Fukuchi Kazumasa (福地 一雅) will remain as an advisor. There is no statement that the other departing officers will remain on the board.

Who is moving to which position
ItemDetails
Scheduled Appointment DateEffective 25 June 2026
Date of departureEffective 25 June 2026
Name of appointeeMakino Junichi (牧野 純一), Nakano Reiko (中野 玲子), Miyajima Kenji (宮嶋 謙二), Ishii Satoshi (石井 智)
Appointee's new positionDirectors, Statutory Auditors, Directors, Representative Director and President, concurrently General Manager of the Sales Promotion Department
Appointee's previous positionNot disclosed, Not disclosed, Not disclosed, Executive Vice President and Director
Name of departing officerKawakami Yutaka (川上 裕), Takeda Masayoshi (竹田 雅好), Sagisaka Keiichi (匂坂 圭一), Kawakami Yutaka (川上 裕), Takeda Masayoshi (竹田 雅好), Fukuchi Kazumasa (福地 一雅)
Former position of departing officerDirectors, Statutory Auditors, Directors, Directors, Statutory Auditors, Representative Director and President, concurrently General Manager of the Sales Promotion Department
New position of departing officerRetirement, Retirement, Retirement, Retirement, Retirement, Adviser
Whether the incumbent will remain in officeFukuchi Kazumasa (福地 一雅) will remain as an advisor. There is no statement that the other departing officers will remain on the board.
Items this document does not state (12)
Resolution dateAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The notice states that personnel changes will be made, but does not provide specific reasons for the changes.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Personnel Changes at a Subsidiary | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori